Clinical Studies Archives - Page 7 of 7

FDA Approves NovoTTF-100LTM System

Approvals, Chemotherapy, Clinical Studies, FDA, FDA/Regulatory, Humanitarian Use Device (HUD), Malignant Pleural Mesothelioma, Medical Devices, Mesothelioma, Premarket Authorization (PMA) pathway

The U.S. FDA approved Novocure’s NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma.

May 23, 2019/by Business Wire

Merck buys Peloton, expands kidney cancer treatment portfolio

Acquisitions, Analysts, Biology, Blockbusters, Business, Cancer, Clinical Studies, Immunotherapies, Kidney Cancer, Renal Cell Carcinoma (RCC)

U.S. drugmaker Merck & Co. Inc. agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.

May 21, 2019/by Reuters Health

Novartis data at AAN show Gilenya is only disease-modifying therapy with proven superiority versus glatiramer acetate in RRMS

Clinical Data, Clinical Studies, Clinical Trials, Disease Modifying Therapy, R&D, Relapsing-Remitting Multiple Sclerosis

Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

May 10, 2019/by Administrator

AskBio Snags $235 Million Investment to Drive Gene Therapy Development

Adeno-Associated Virus (AAV), Business, Clinical Studies, DNA, Fast Track Designation, FDA, Gene Therapy, Heart Failure, Pompe disease, Rare Genetic Diseases

Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.

April 11, 2019/by BioSpace

BioLineRx, Merck Expand Immuno-Oncology Collaboration in Pancreatic Cancer

Biopharmaceutical, Blockbusters, Clinical Studies, Collaboration, Immuno-oncology, Pancreatic Cancer, PD-1/PD-L1 inhibitors, Peptides, Short Synthetic Peptides, Solid Tumors

BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.

July 30, 2018/by PR Newswire

Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint

Biopharma, Bruton's Tyrosine Kinase (BTK) Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Progression-Free Survival (PFS), Small Lymphocytic Lymphoma (SLL)

AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.

May 24, 2018/by PR Newswire